These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19702237)

  • 1. Health Canada releases guidance documents for subsequent entry biologics.
    Robertson S
    Health Law Can; 2009 May; 29(3):51-2. PubMed ID: 19702237
    [No Abstract]   [Full Text] [Related]  

  • 2. Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics.
    Looper YJ
    Curr Opin Drug Discov Devel; 2010 Mar; 13(2):247-56. PubMed ID: 20205058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No longer "if," but "when": the coming abbreviated approval pathway for follow-on biologics.
    Kelly JJ; David M
    Food Drug Law J; 2009; 64(1):115-48. PubMed ID: 19998743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of biologics by food animal practitioners.
    Herrick JB
    J Am Vet Med Assoc; 1990 Jun; 196(12):1937. PubMed ID: 2365615
    [No Abstract]   [Full Text] [Related]  

  • 5. Inspection of veterinary biologics in the United States.
    Randall DC
    Dev Biol Stand; 1992; 79():163-70. PubMed ID: 1286751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APHIS biologics personnel hear from constituents, consumers.
    Gloyd JS
    J Am Vet Med Assoc; 1992 Oct; 201(7):976-7. PubMed ID: 1429145
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulation of natural health products in Canada.
    Smith A; Jogalekar S; Gibson A
    J Ethnopharmacol; 2014 Dec; 158 Pt B():507-10. PubMed ID: 24969823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The road to the biotech revolution: highlights of 100 years of biologics regulation.
    Bren L
    FDA Consum; 2006; 40(1):50-7. PubMed ID: 16528828
    [No Abstract]   [Full Text] [Related]  

  • 9. Testing of veterinary biologics in the United States.
    Bunn TO
    Dev Biol Stand; 1992; 79():187-92. PubMed ID: 1286757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current USDA procedures for licensing biotechnology-derived veterinary biologicals.
    Gay CG
    Dev Biol Stand; 1992; 79():65-74. PubMed ID: 1286767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Data protection for " innovative drugs"--guidance now final.
    McMahon E; Reguly T
    Health Law Can; 2009 May; 29(3):44-5. PubMed ID: 19702233
    [No Abstract]   [Full Text] [Related]  

  • 12. APHIS clarifies rules on biologics production.
    J Am Vet Med Assoc; 2015 Jul; 247(2):133. PubMed ID: 26349093
    [No Abstract]   [Full Text] [Related]  

  • 13. Biologics for inflammatory bowel disease: drug approval and monitoring in the United States.
    Tremaine WJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):735-41. PubMed ID: 17129810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patentability of biologics in Canada: beyond patentable subject matter.
    Aumand L; Norman J
    Pharm Pat Anal; 2013 Jul; 2(4):431-3. PubMed ID: 24237117
    [No Abstract]   [Full Text] [Related]  

  • 15. Food and Drug Administration regulations and licensure.
    Barker LF
    Fed Proc; 1975 May; 34(6):1522-4. PubMed ID: 1126452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ideas on the organization of a national laboratory for the control of biologics].
    Nájera R; Mateos JB
    Rev Sanid Hig Publica (Madr); 1983; 57(3-4):355-7. PubMed ID: 6669911
    [No Abstract]   [Full Text] [Related]  

  • 17. The transmissible spongiform encephalopathy agents: concerns and responses of United States regulatory agencies in maintaining the safety of biologics.
    Asher DM
    Dev Biol Stand; 1999; 100():103-18. PubMed ID: 10616181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Importance of control tests of biological products in relation to the use in practice].
    Fernández de Castro J
    Salud Publica Mex; 1979; 21(4):361-8. PubMed ID: 550315
    [No Abstract]   [Full Text] [Related]  

  • 19. Preparing for subsequent entry biologics in dermatology and rheumatology in Canada.
    Papp K; Bourcier M; Ho V; Burke K; Haraoui B
    J Cutan Med Surg; 2013; 17(5):340-6. PubMed ID: 24067855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The challenge of follow-on biologics for treatment of multiple sclerosis.
    Reingold SC; Steiner JP; Polman CH; Cohen JA; Freedman MS; Kappos L; Thompson AJ; Wolinsky JS
    Neurology; 2009 Aug; 73(7):552-9. PubMed ID: 19687456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.